ALOX5 is a promising molecular target for the treatment of CML, as it has been demonstrated that a small molecule inhibitor of ALOX5 significantly delays leukemia onset in mice [29]. The gene discussed is ALOX5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.